\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched three new calls for the purposes of training and capacity building in its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs), and more in general to the public and private sector. More information on this initiative can be found here or in this JRC Brochure.
It concerns the following three calls:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Agro-Food, Environment
The Sustainable Blue Economy Partnership brings together 74 partner institutions from 32 countries and the European Commission under Horizon Europe. They have recently opened a new transnational access call to marine and maritime research infrastructures with several intermediary deadlines. The next cut-off is 20 October 2026 at 11:00 CEST. T... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
